Market Cap 33.42B
Revenue (ttm) 1.70B
Net Income (ttm) -190.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11.22%
Debt to Equity Ratio 0.06
Volume 578,600
Avg Vol 1,327,874
Day's Range N/A - N/A
Shares Out 138.32M
Stochastic %K 63%
Beta 1.62
Analysts Strong Sell
Price Target $255.80

Company Profile

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples und...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 650 980 9190
Address:
13011 McCallen Pass, Building A Suite 100, Austin, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 24 at 1:38 PM
$NTRA RSI: 58.64, MACD: 2.9407 Vol: 6.57, MA20: 237.46, MA50: 231.82 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 ¡ Reply
justiceforb_85
justiceforb_85 Jan. 23 at 4:03 AM
$EXEL might be worth a buy considering NDA for zanzalintinib this year and partnership in CRC with $NTRA.
0 ¡ Reply
Cheetah007
Cheetah007 Jan. 21 at 4:12 AM
$NTRA nothing seems to be able to stop this beast.
0 ¡ Reply
SuperGreenToday
SuperGreenToday Jan. 19 at 8:54 PM
$NTRA Share Price: $231.23 Contract Selected: Jul 17, 2026 $230 Calls Buy Zone: $24.91 – $30.77 Target Zone: $43.43 – $53.08 Potential Upside: 65% ROI Time to Expiration: 178 Days | Updates via https://fxcapta.com/stockinfo/
0 ¡ Reply
Itzx3ro
Itzx3ro Jan. 16 at 2:53 PM
$NTRA random dump at the open triggered my stop 😭
0 ¡ Reply
v92
v92 Jan. 14 at 2:45 AM
$NTRA Well this should moon tomorrow.
1 ¡ Reply
kev100
kev100 Jan. 14 at 1:31 AM
$NTRA NTRA's presentation at the JPM Healthcare Conference. Key takeaways: • Record 2025 across all segments, with Signatera MRD posting its fastest growth ever • Q4 revenue up ~39% YoY, with record margins and over $100M in free cash flow for 2025 • Next-generation ultra-sensitive Signatera (phased + structural variants) planned for launch in 2026 • AI-enhanced MRD model aimed at further improving recurrence risk prediction • Foresight acquisition expands into lymphoma and strengthens sensitivity leadership • New Fetal Focus single-gene NIPT showing strong early traction; early cancer detection enrolling ahead of plan Potential stock impact: • Results and outlook appear to meet or exceed expectations on growth and margins • Accelerating Signatera adoption and rising ASPs improve long-term revenue visibility • A widening technology and data moat (ultra-sensitivity, AI, clinical evidence) supports a premium valuation
0 ¡ Reply
ZacksResearch
ZacksResearch Jan. 13 at 4:48 PM
$NTRA teams up with $NVDA — AI just made a serious move into precision medicine. 🚀 The partnership focuses on training multimodal AI models to enable faster, more scalable analysis of complex medical data, aiming to improve precision care. Discover what this AI collaboration could unlock next 👉 https://www.zacks.com/stock/news/2816598/ntra-nvda-partner-to-improve-ai-models-for-precision-medicine?cid=sm-stocktwits-2-2816598-teaser-28652&ADID=SYND_STOCKTWITS_TWEET_2_2816598_TEASER_28652
0 ¡ Reply
ZacksResearch
ZacksResearch Jan. 13 at 3:48 PM
$NTRA partners with $NVDA to enhance precision medicine! 🤝 Natera's new collaboration with NVIDIA aims to enhance AI in healthcare by speeding up bioinformatics workflows and training large-scale models. 🚀 The partnership promises to unlock potential new revenue streams and strengthen biopharma ties for NTRA, boosting its competitive edge. Discover the full impact here 👉 https://www.zacks.com/stock/news/2816598/ntra-nvda-partner-to-improve-ai-models-for-precision-medicine?cid=sm-stocktwits-2-2816598-body-28640&ADID=SYND_STOCKTWITS_TWEET_2_2816598_BODY_28640
0 ¡ Reply
JosephSmith835
JosephSmith835 Jan. 12 at 5:35 PM
$NTRA $LC Diagnostics angle
0 ¡ Reply
Latest News on NTRA
Alger Mid Cap Focus Fund Q4 2025 Portfolio Update

Jan 22, 2026, 5:15 AM EST - 5 days ago

Alger Mid Cap Focus Fund Q4 2025 Portfolio Update

EXAS GH HOOD NBIS RBLX


Alger Spectra Fund Q4 2025 Portfolio Update

Jan 19, 2026, 10:20 AM EST - 8 days ago

Alger Spectra Fund Q4 2025 Portfolio Update

GOOG META MSFT NBIS


Natera Acquires Foresight Diagnostics

Dec 5, 2025, 7:00 AM EST - 7 weeks ago

Natera Acquires Foresight Diagnostics


Natera Integrates with Flatiron Health's OncoEMRÂŽ Platform

Nov 12, 2025, 8:00 AM EST - 2 months ago

Natera Integrates with Flatiron Health's OncoEMRÂŽ Platform


Natera, Inc. (NTRA) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 8:36 PM EST - 2 months ago

Natera, Inc. (NTRA) Q3 2025 Earnings Call Transcript


Natera Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 2 months ago

Natera Reports Third Quarter 2025 Financial Results


Natera to Report its Third Quarter Results on November 6, 2025

Oct 30, 2025, 7:00 AM EDT - 3 months ago

Natera to Report its Third Quarter Results on November 6, 2025


Natera Named to Fast Company's Next Big Things in Tech List

Oct 16, 2025, 8:00 AM EDT - 3 months ago

Natera Named to Fast Company's Next Big Things in Tech List


Can Natera Stock Reach $500?

Sep 15, 2025, 10:10 AM EDT - 4 months ago

Can Natera Stock Reach $500?


Natera Provides Update on Patent Litigation with NeoGenomics

Aug 29, 2025, 8:18 AM EDT - 5 months ago

Natera Provides Update on Patent Litigation with NeoGenomics


OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 24 at 1:38 PM
$NTRA RSI: 58.64, MACD: 2.9407 Vol: 6.57, MA20: 237.46, MA50: 231.82 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 ¡ Reply
justiceforb_85
justiceforb_85 Jan. 23 at 4:03 AM
$EXEL might be worth a buy considering NDA for zanzalintinib this year and partnership in CRC with $NTRA.
0 ¡ Reply
Cheetah007
Cheetah007 Jan. 21 at 4:12 AM
$NTRA nothing seems to be able to stop this beast.
0 ¡ Reply
SuperGreenToday
SuperGreenToday Jan. 19 at 8:54 PM
$NTRA Share Price: $231.23 Contract Selected: Jul 17, 2026 $230 Calls Buy Zone: $24.91 – $30.77 Target Zone: $43.43 – $53.08 Potential Upside: 65% ROI Time to Expiration: 178 Days | Updates via https://fxcapta.com/stockinfo/
0 ¡ Reply
Itzx3ro
Itzx3ro Jan. 16 at 2:53 PM
$NTRA random dump at the open triggered my stop 😭
0 ¡ Reply
v92
v92 Jan. 14 at 2:45 AM
$NTRA Well this should moon tomorrow.
1 ¡ Reply
kev100
kev100 Jan. 14 at 1:31 AM
$NTRA NTRA's presentation at the JPM Healthcare Conference. Key takeaways: • Record 2025 across all segments, with Signatera MRD posting its fastest growth ever • Q4 revenue up ~39% YoY, with record margins and over $100M in free cash flow for 2025 • Next-generation ultra-sensitive Signatera (phased + structural variants) planned for launch in 2026 • AI-enhanced MRD model aimed at further improving recurrence risk prediction • Foresight acquisition expands into lymphoma and strengthens sensitivity leadership • New Fetal Focus single-gene NIPT showing strong early traction; early cancer detection enrolling ahead of plan Potential stock impact: • Results and outlook appear to meet or exceed expectations on growth and margins • Accelerating Signatera adoption and rising ASPs improve long-term revenue visibility • A widening technology and data moat (ultra-sensitivity, AI, clinical evidence) supports a premium valuation
0 ¡ Reply
ZacksResearch
ZacksResearch Jan. 13 at 4:48 PM
$NTRA teams up with $NVDA — AI just made a serious move into precision medicine. 🚀 The partnership focuses on training multimodal AI models to enable faster, more scalable analysis of complex medical data, aiming to improve precision care. Discover what this AI collaboration could unlock next 👉 https://www.zacks.com/stock/news/2816598/ntra-nvda-partner-to-improve-ai-models-for-precision-medicine?cid=sm-stocktwits-2-2816598-teaser-28652&ADID=SYND_STOCKTWITS_TWEET_2_2816598_TEASER_28652
0 ¡ Reply
ZacksResearch
ZacksResearch Jan. 13 at 3:48 PM
$NTRA partners with $NVDA to enhance precision medicine! 🤝 Natera's new collaboration with NVIDIA aims to enhance AI in healthcare by speeding up bioinformatics workflows and training large-scale models. 🚀 The partnership promises to unlock potential new revenue streams and strengthen biopharma ties for NTRA, boosting its competitive edge. Discover the full impact here 👉 https://www.zacks.com/stock/news/2816598/ntra-nvda-partner-to-improve-ai-models-for-precision-medicine?cid=sm-stocktwits-2-2816598-body-28640&ADID=SYND_STOCKTWITS_TWEET_2_2816598_BODY_28640
0 ¡ Reply
JosephSmith835
JosephSmith835 Jan. 12 at 5:35 PM
$NTRA $LC Diagnostics angle
0 ¡ Reply
THE_Monkey_Banana_Genius
THE_Monkey_Banana_Genius Jan. 12 at 3:05 PM
0 ¡ Reply
Jessypenny
Jessypenny Jan. 9 at 9:56 AM
Biotech Breakout Alert: The Momentum Club The sector is on fire as we head into JPM week! While the $IBB hits new highs, these 4 names are leading the charge with relentless 52-week high streaks: $DRTS — The star of the week. 4 consecutive days of 52-week highs! With the FDA PMA submission live and ASCO GI data validating the pancreatic platform, Alpha Tau is entering an era of unprecedented growth. Institutional accumulation is undeniable. $BIIB — 4-day streak. Reached $186.91 yesterday. Massive confidence following the VALOR study updates and stabilized base business. $REGN — 3-day streak. Hit $812.27. Analysts are raising targets to $1,000+ as Dupixent growth shows no signs of slowing. $NTRA — 4-day streak. Touching $254.40. The oncology diagnostics king is benefiting from a massive shift toward personalized medicine. The "January Effect" is real. $DRTS is leading the small-cap charge while the giants provide the floor.
0 ¡ Reply
justiceforb_85
justiceforb_85 Jan. 8 at 11:24 PM
$NTRA added more.
0 ¡ Reply
THE_Monkey_Banana_Genius
THE_Monkey_Banana_Genius Jan. 8 at 7:50 PM
$NTRA any news today? Long
2 ¡ Reply
v92
v92 Jan. 8 at 7:30 PM
$NTRA News? What am I missing?
0 ¡ Reply
ZacksResearch
ZacksResearch Jan. 8 at 5:32 PM
Is $EXEL's zanzalintinib the next big thing in oncology? 🚀 With a promising phase III study expected to start in mid-2026 and a new drug application submitted for metastatic CRC, Exelixis is positioning zanzalintinib as a potential game-changer. Their collaboration with $NTRA could reshape MRD-guided therapies. Discover the full potential here 👉 https://www.zacks.com/stock/news/2814082/exel-collaborates-with-natera-for-late-stage-colorectal-cancer-study?cid=sm-stocktwits-2-2814082-body-28037&ADID=SYND_STOCKTWITS_TWEET_2_2814082_BODY_28037
0 ¡ Reply
topstockalerts
topstockalerts Jan. 7 at 5:00 PM
Exelixis and Natera announced a collaboration on a pivotal Phase 3 trial in resected stage II/III colorectal cancer patients. The study, called STELLAR-316, will evaluate Exelixis’ oral kinase inhibitor zanzalintinib, with or without an immune checkpoint inhibitor, in patients identified as having molecular residual disease (MRD) using Natera’s Signatera test. The randomized trial targets a high-risk population with limited treatment options, as about 20% of stage II/III colorectal cancer patients remain MRD-positive after definitive therapy and face a high risk of recurrence. Disease-free survival will serve as the primary endpoint, with clearance of circulating tumor DNA as a key secondary endpoint. Exelixis expects to initiate the study in mid-2026, and success could position zanzalintinib as the first MRD-guided treatment in this setting. $EXEL $NTRA
0 ¡ Reply
BillionerOfKing
BillionerOfKing Jan. 7 at 4:56 PM
$NTRA Current Stock Price: $255.09 Contracts to trade: $260 NTRA Jan 16 2026 Call Entry: $2.30 Exit: $4.22 ROI: 83% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 ¡ Reply
S_Franconi
S_Franconi Jan. 7 at 1:10 PM
$NTRA Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer https://investor.natera.com/news/news-details/2026/Exelixis-and-Natera-to-Collaborate-on-STELLAR-316-a-Phase-3-Pivotal-Trial-of-Zanzalintinib-for-Patients-with-Colorectal-Cancer-2026-jxHhxDByJm/default.aspx
0 ¡ Reply
WAJeff
WAJeff Jan. 6 at 7:49 PM
$NTRA $248.01 ath
0 ¡ Reply
THE_Monkey_Banana_Genius
THE_Monkey_Banana_Genius Jan. 6 at 3:14 PM
$GH $NTRA $CRSP $BEAM very nice day. Long. Any news?
0 ¡ Reply
50bps
50bps Jan. 6 at 3:19 AM
0 ¡ Reply